Proposal to list enteral feed with fibre 0.83 kcal/ml (Nutrison 800 Complete Multi Fibre)
PHARMAC is seeking feedback on a proposal to fund a new formulation of enteral feed for dietary management of patients with low energy and/or low fluid requirements.
This proposal is as a result of a provisional agreement with Nutricia Limited.
In summary, this proposal would result in, from 1 November 2016:
- Enteral feed with fibre 0.83 kcal/ml (Nutrison 800 Complete Multi Fibre) being funded in the community and DHB hospitals for patients with low energy and/or low fluid requirements subject to the same Special Authority criteria that applies to Standard Supplements.
Feedback sought
PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Monday, 12 September 2016 to:
Matthew Tyson
Therapeutic Group Manager
PHARMAC
PO Box 10 254
Wellington 6143
Email: matthew.tyson@pharmac.govt.nz
Fax: 04 460 4995
All feedback received before the closing date will be considered by PHARMAC’s Board (or its delegate) prior to making a decision on this proposal.
Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.
We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.
Details of the proposal
It is proposed that, from 1 November 2016:
- Nutrison 800 Complete Multi Fibre would be listed in Section D of the Pharmaceutical Schedule (in the community) and in Part II of Section H (the Hospital Medicines List, or HML) at the following, prices and subsidies (ex-manufacturer, excluding GST):
|
Pharmaceutical |
Brand |
Form |
Pack size |
Price and subsidy |
|---|---|---|---|---|
|
Enteral feed with fibre 0.83 kcal/ml |
Nutrison 800 Complete Multi Fibre |
Liquid |
1,000 ml OP |
$5.29 |
- Nutrison 800 Complete Multi Fibre would be subject to the Special Authority Criteria for Standard Supplements (SA1554). Please note there are no proposed changes to the Special Authority criteria as a result of this listing.
- Nutrison 800 Complete Multi Fibre would be subject to the restrictions for Standard Feeds (RS1214). Please note there are no proposed changes to the Standards Feeds restrictions as a result of listing.
Existing Special Authority criteria and Hospital Medicines List (HML) restrictions for these pharmaceuticals can be found on PHARMAC’s website at the links below.
https://www.pharmac.govt.nz/latest/SA1554.pdf [form no longer available]
https://www.pharmac.govt.nz/latest/RS1214.pdf [form no longer available]
Background
An application to list Nutrison 800 Complete Multi Fibre was considered by the Special Foods Subcommittee at its July 2015 meeting. The Special Foods Subcommittee recommended listing in both community and hospital with a medium priority. This recommendation was ratified by the Pharmacology and Therapeutics Advisory Committee (PTAC) in November 2015. Details of the minutes are available via the application tracker on our website here:
Currently patients in the hospital and community with low energy requirements, who require an enteral feed, must use alternative funded feeds which must be manipulated (i.e. diluted with water) to achieve lower calorie levels. Our clinical advice indicates that manipulating feeds to achieve lower calorie levels involves product wastage. Such patients include those with low mobility or who are immobile, the elderly, long term tube fed, people who are obese and those gaining inappropriate weight.